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definitively established due to some controversial findings, 
the possible reasons of which demand further research with 
prospective and uniform protocols and analysis, great number 
of pts and adequate follow-up period. 
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Carbon ion radiotherapy for stage I non-small cell lung 
cancer: A Meta-analysis of 369 patients 
Q. Zhang
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Purpose or Objective: To synthesize and compare available 
evidence considering the effectiveness of carbon-ion 
radiotherapy for stage I non-small cell lung cancer. 
 
Material and Methods: To synthesize and compare available 
evidence considering the effectiveness of carbon-ion 
radiotherapy for stage I non-small cell lung cancer. Methods: 
A comprehensive search was conducted in the Cochrane 
Library, PubMed, EMBASE,Web of Science and Chinese 
Biomedical Literature Database (from inception to Feb 2015). 
Selection of studies, and extracting data were performed by 
two reviewers independently. Outcomes were analyzed by 
random-effects model meta-analysis and reported as odds 
ratio (OR) with 95% confidence intervals (CI). The meta-
analysis was conducted with STATA 12.0 software. 
 
Results: Eight trials(369 patients) were included, the meta 
analysis showed that the one year local control rate(LCR) was 
OR=0.89(95%CI:0.81,0.90),two years LCR was 
OR=0.81(95%CI:0.72,0.89),three years LCR was 
OR=0.64(95%CI:0.55,0.73),four years LCR was 
OR=0.23(95%CI:0.13,0.33) and five years LCR was 
OR=0.70(95%CI:0.67,0.73).the one year overall survival(OS) 
was OR=0.94(95%CI:0.88,0.99),two years OS was 
OR=0.85(95%CI:0.70,1.00),three years OS was 
OR=0.64(95%CI:0.50,0.78), four years OS was 
OR=0.29(95%CI:0.18,0.40) and five years OS was 
OR=0.34(95%CI:0.19,0.49).the one year progression-free 
survival(PFS) was OR=0.79(95%CI:0.69,0.89), two years PFS 
was OR=0.63(95%CI:0.52,0.75),three years PFS was 
OR=0.39(95%CI:0.28,0.51),four years PFS was 
OR=0.20(95%CI:0.10,0.29) and five years PFS was 
OR=0.08(95%CI:0.02,0.15).the recurrence was 
OR=0.46(95%CI:0.39,0.53) and distant metastasis was 
OR=0.20(95%CI:0.14,0.26). 
 
Conclusion: Carbon beam radiotherapy, which is an excellent 
new modality in terms of a high local control and survival, 
may be a valid alternative to surgery for Stage I cancer, 
especially for elderly and inoperable patients. 
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Purpose or Objective: Stereotactic ablative radiotherapy is 
an emerging non-invasive technique for the treatment of lung 
lesions. Both primary lesions and metastases may benefit 
from this approach, even in patients with low respiratory 
reserve. This work describes and evaluates institutional 
experience of SABR in lung location. 
 
Material and Methods: From May´12 to November´14, 82 
lesions in 67 patients were irradiated. 57 lesion were primary 
lung tumors and 25 metastases. Immobilization systems used 
in each patient was abdominal compressor and vacuum 
cushion o head-and-shoulders mask. An ITV was defined using 
three CT scans in three different phases of the respiratory 
cycle or with 4D RPM-Varian® system. The PTV was obtained 
by uniformly 5 mm ITV expanding. BED prescription was 
always over 100 Gy10 in 3-8 fractions following a risk-adapted 
protocol. 8 patient treatments were performed on a Clinac 
iXTM and 74 treatments on a TruebeamTM with high 
definition MLC. Volumetric modulated arc therapy 
(RapidArcTM) was mostly used, and image-guided RT was 
performed with cone-beam CT (CBCT). Intra-fraction 
movement was controlled by post-treatment CBCT and infra-
red ExacTrac. 
 
Results: Median age was 75y.o.(44-89). The median GTV/PTV 
size was 3.2/27.15cm3 (0.2-129.9/5.90-263.90). Intra-
fraction movement in all cases was less than 5mm according 
to post-treatment CBCT. At a median follow-up of 7(1-30) 
months, overall l local control was 92.7%, 89.5% for primary 
lesions and 100% for metastases. Mean overall survival was 18 
months for primary lesion (14.7-21.33 [95%]). No toxicities 
over G3 have been collected. 
 
Conclusion: VMAT based ablative radiotherapy achieves 
excellent control rates in both primary lesions and 
metastases. Overall survival also depends on specific 
characteristics of the patient. 
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Purpose or Objective: Receiving Radio(chemo)therapy 
[R(C)T] for pulmonary tumors some patients have or develop 
necrosis or fistulae (N/F) within the area of the treated 
tumor. Partially such N/F result in fatal complications like 
mediastinitis or pneumonia whereas other affected patients 
achieve good local control rates with long term survival after 
R(C)T. By retrospectively analyzing such cases we are aiming 
at identifying factors that might have an impact on the 
course of disease and should pre-therapeutically be 
considered in future. 
 
Material and Methods: Retrospective analysis of patients 
coming up with N/F in temporal association with chest RT 
applied at the University Medical Center Freiburg from 2006 
to 2013. Clinical and radiation parameters have been 
evaluated, acute and late toxicity, complications, clinical 
and imaging follow up have been assessed and will be 
analyzed with respect to local control and overall survival. 
 
Results: We identified 40 patients irradiated for pulmonary 
malignancies (mainly centrally located NSCLC, UICC IIIB/IV; 
16 female, 24 male; median age 64 years; 15 squamous cell-, 
15 adenocarcinoma, 10 other) who developed N/F in 
temporal association with chest RT. Intention of treatment 
was curative in 31 and palliative in 9 patients. 25 patients 
received R(C)T, 15 received RT alone with a median total 
dose of 54 Gy (14-72Gy). 26 patients revealed a necrotic 
primary tumor, 6 additionally necrotic lymph node 
metastases (LNM), 8 necrotic LNM, exclusively. In 34 lesions 
necrosis was found previous to RT, in 3 cases it occurred 
during, in 3 cases after RT.14 patients showed fistulae, all 
fistulae with esophageal or mediastinal involvement emerged 
after RT. For 16 patients G3, for 6 G4 toxicities have been 
reported, one patient died in consequence of an esophago-
tracheal fistula. All patients with N/F-connection to the 
esophagus revealed toxicities ≥G3, whereas some patients 
with centrally necrotic tumor and fistula without esophageal 
involvement revealed excellent long term follow ups. Median 
survival was 12,6 months (median FU 6,9 months). All 
patients with esophago-tracheal fistula died before reaching 
the median. Histology and location of the necrotic lesions 
didn’t show any significant impact on survival. 
 
Conclusion: R(C)T of pulmonary malignancies for patients 
with N/ F can be associated with high toxicity. One essential 
factor with impact on the clinical course seems to be the 
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involvement of the esophagus. Without, courses with low 
complications and good local control are possible. 
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Purpose or Objective: The most common reason for patients 
(pts) with localized NSCLC to be deemed medical inoperable 
is Chronic Obstructive Pulmonary Disease (COPD). COPD is 
associated with severe morbidity and mortality. It is not 
known if the prognosis of COPD pts is so poor that diagnosed 
localized lung cancer may only have little impact on survival. 
The aim of this study was to compare survival in SBRT treated 
COPD pts unfit for surgery and COPD pts without a malignant 
diagnosis. 
 
Material and Methods: Data for the group of SBRT treated 
NSCLC pts from our institution were prospectively recorded 
from 2007 until 2013. The non-malignant control group was 
retrospectively selected among pts referred to the 
Department of Respiratory Medicine from 2005 until 2011 due 
to suspected lung cancer, which was subsequently ruled out. 
From both groups pts were selected for the present analysis 
if spirometry fulfilled the criteria for COPD defined as the 
ratio between forced expiratory volume in 1 second (FEV1) 
and forced vital capacity (FVC) less than 70%. The COPD was 
classified according to international GOLD criteria as mild, 
moderate, severe, or very severe based on FEV1 in percent of 
predicted (FEV1%pred). Propensity score matching (PSM) was 
performed to reduce confounding between the two groups 
based on age, gender, and FEV1%pred. The treatment 
survival outcome variable was calculated using the Kaplan-
Meier method. Log rank test was used for testing differences 
in survival rates. 
 
Results: 102 SBRT treated pts (NSCLC group) and 573 pts 
without malignant disease (non-malignant group) were 
enrolled after a spirometry revealed COPD. No SBRT-related 
deaths were observed. Pts in the NSCLC group were older 
(p<0.05) and had worse FEV1%pred (p<0.05). PSM identified 
102 pts from each group with similar characteristics: mean 
age of 72.7 years, FEV1%pred of 52, and 54 women. In the 
matched comparison a significant difference in the median 
overall survival was observed, 57 months vs. 87 months in the 
NSCLC and non-malignant groups, respectively p<0.05 (figure 
1). Subgroup analyses of pts with mild/moderate COPD and 
pts with severe/very severe COPD showed that the difference 
in mOS in the unmatched and matched comparison was more 
pronounced in pts with mild/moderate COPD. 
 
 
 
Conclusion: In a matched comparison, SBRT treated COPD 
pts with localized NSCLC had worse survival compared with 
COPD pts without a malignant diagnosis. Despite the serious 
prognosis of COPD, a diagnosis of localized NSCLC affected 
the survival in COPD pts. 
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Purpose or Objective: To evaluate efficacy and safety of 
Cyberknife radiosurgery (CKRS) in patients with spinal 
metastasis from lung cancer. 
 
Material and Methods: From July 2011 to October 2014, 64 
patients received CKRS for spinal metastasis from 
pathologically confirmed lung cancer. Medical record of 75 
lesions in 64 patients retrospectively reviewed. Pain control, 
radiological tumor control, especially epidural mass, and 
treatment related complications such as vertebral 
compression fracture and pain flare were assessed. 
Radiologic response was assessed following RECIST criteria. 
Pain response was defined according to International Bone 
Metastases Consensus Working Party palliative RT endpoints. 
 
Results: Median age of patients with bone metastasis was 61 
years (36-81 years). 42 patients (63.6%) had bone metastasis 
at initial diagnosis. Mean tumor diameter was 2.59 cm (1.2 
cm-8.3cm), and 16 patients had epidural extension. was 
found in 16 patients (21.3%). Radiation dose were 14 – 32 Gy 
per 1-4 fx (BED(α/β=10): 28.8-57.6 Gy, median 41.6 Gy). 
Radiologic evaluation with CT or MR after CKRS was done at 
54 lesions (72.0%). Pain response was assessed in 59 lesions 
(78.7%). With median follow-up of 10.5 months (1 – 40 
months), local tumor progression was found in 9 lesions 
(12.0%), and median time to progression was 10.1 months. 1 
year and 2 year local progression free survival rate was 84.6% 
and 79.7%. Among 16 lesions with epidural extension, 11 
lesions had evaluated by CT or MR, and the tumor regression 
achieved in 8 lesions (72.7%). Pain response rate after CKRS 
was 83.1% (CR : 28.6% , PR : 71.4% , SD : 20.4%). All patients 
tolerated the CKRS course well. Compression fracture was 
found in 31 lesions (41.3%) but only 13 lesions(17.3%) 
collapsed among 54 lesions(72.0%) with osteolysis. 
 
Conclusion: Cyberknife radiosurgery is an effective for local 
control and safe treatment modality to osteolytic spinal 
metastasis from lung cancer. 
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Purpose or Objective: Following curative intent 
radiotherapy, up to 50% of patients with non-small cell lung 
cancer (NSCLC) experience local recurrence. This may be 
associated with significant symptomatology such as airways 
obstruction, haemoptysis and pain. Re-irradiation may be 
useful to palliate symptoms and to attempt cure, but little is 
known about effectiveness, usage rates, techniques used and 
clinical outcome. We report the incidence of thoracic re-
irradiation following curative intent thoracic radiotherapy. 
